Pressure BioSciences, Inc. (PBIO) Announces $7.24M Debt-to-Equity Swap as it Prepares for 2018 Uplisting to National Stock Exchange
Equity swap further boosts Pressure BioSciences’ plans to uplist to a major stock exchange later this year Latest deal brings total debt-to-equity conversions to over $13.6M in past 30 days 2015/2016 debentures, line-of-credit and promissory note, plus various short-term debt, now converted to equity Company’s recently acquired Pre-EMT™ platform, allowing for improved protein-based drug development, has significant market potential and adds to a string of technological developments Pressure BioSciences Inc.’s (OTCQB: PBIO) ambitions to achieve listing on a major stock exchange this year have taken another major step forward as yet another group of debt holders have agreed to a…
